Articles tagged with Antidepressants
A small clinical trial of escitalopram, an antidepressant medication, found no conclusive benefit in treating kleptomania. However, the results suggest that some medications may still be effective for certain patients.
A study found no difference in the relapse rate of people with compulsive-buying disorder when taking escitalopram compared to those on a placebo, contradicting previous research findings. The results may be due to differences in biological roots among individuals with the disorder.
A University of Iowa study found antidepressant treatment improves post-stroke cognitive abilities, including executive function, in stroke survivors. The improvements occurred 21 months after treatment ended and were independent of changes in depression.
A CIHR-funded study found that while antidepressants reduce alcohol consumption in men with depression, this effect is lost for women. Men taking antidepressants consumed significantly less alcohol than depressed men who did not use antidepressants.
A new care management program, AIM, has been shown to be significantly more effective than standard treatment in improving depression in stroke survivors. The study found that 39% of patients who received AIM had complete remission from depression after 12 weeks of treatment.
A study published in JAMA found that citalopram was superior to placebo in reducing depressive symptoms in patients with coronary artery disease. The treatment also improved perceived social support and daily function.
A study of 5,008 adults found that daily use of selective serotonin reuptake inhibitors (SSRIs) is associated with a doubled risk of certain fractures. The use of SSRIs was also linked to an increased risk of falls and decreased bone mineral density.
A new study found that patients who initiate general discussions about antidepressant medication are more likely to be thoroughly evaluated for depression than those with brand-specific requests or no request. This increase in history-taking also leads to better provision of initial care and diagnostic accuracy.
Chronic kidney disease affects a significant portion of the UK population, particularly elderly individuals taking multiple medications. Healthcare professionals require specific guidance on using drugs that can cause or be altered by kidney disease, as 'use with caution' advice is often insufficient.
A large Finnish study found that individuals taking antidepressant medications have a higher risk of additional suicide attempts, yet a lower risk of dying from suicide or other causes. The study showed a significant association between antidepressant use and reduced mortality rates.
The National Institute of Mental Health is funding five new projects to investigate the relationship between antidepressant medications and suicidal thoughts or actions. Studies will analyze data from various sources, including the FDA, VA, and Medicare records, to determine the effectiveness of different depression treatments in reduc...
A new study by Duke University Medical Center researchers found that depression itself increases mortality risk in heart failure patients, not the use of antidepressant medications. The study analyzed over 1,000 depressed patients with heart failure and found a 15% higher death rate among those who were depressed.
Researchers found significant variation between individuals with depression and healthy women, particularly in the mu-opioid system involved in stress and emotions. The study suggests that these differences may predict treatment response, highlighting the need for personalized approaches to depression treatment.
A US study found an inverse relationship between antidepressant prescriptions and child suicide rates, with counties having high prescription rates showing lower suicide rates. The study predicts that no SSRI prescriptions would lead to 253 more suicides per year among children and adolescents.
Regular follow-up is essential during antidepressant treatment due to individual variability in response, according to Dr. Greg Simon. The author suggests maintaining a connection between patients and providers to address potential concerns and provide support.
A six-year study, STAR*D, found that 67% of patients achieved full remission after one to four treatment steps. Careful monitoring and collaboration between patients and clinicians are crucial for improving outcomes.
A new study found that low doses of sertraline taken before the onset of menstruation may be an effective treatment for moderate-to-severe premenstrual syndrome. Researchers also tested two other dosing strategies, including daily medication throughout the menstrual cycle and symptom-onset dosing.
A large-scale clinical trial funded by the NIH found that commonly prescribed antipsychotic medications for Alzheimer's patients with delusions and aggression have limited effectiveness, while increasing the risk of severe side effects. The study suggested that alternative treatments may be more suitable for this vulnerable population.
Researchers developed a new method for treating post-concussion syndrome, known as regulated exercise, which involves individualized exercise programs to improve brain function and reduce symptoms. The treatment has shown promising results in reducing depressive symptoms and improving patient outcomes.
A nationwide study led by USC professor Lon Schneider found that most Alzheimer's patients prescribed antipsychotic drugs discontinue use due to severe side effects, despite showing some effectiveness in managing delusions and agitation. The study suggests that these medications should be used with caution and only when necessary.
A study at the American Society of Plastic Surgeons annual meeting found that plastic surgery can lead to a significant decrease in antidepressant medication use among patients. Cosmetic surgery procedures such as breast augmentation, tummy tucks, and facelifts were associated with improved self-esteem and reduced antidepressant needs.
A study found associations between genetic polymorphisms and response to antidepressant treatment, suggesting personalized treatment options. Patients carrying specific gene variations had better response rates to norepinephrine reuptake inhibitors (NRIs) or selective serotonin reuptake inhibitors (SSRIs).
A recent study found that nearly one in five stroke survivors suffer from depression, with only 22% of those taking antidepressants being effective. Researchers hope to increase identification and treatment by educating physicians, patients, and families about the risk of depression after stroke.
A recent study published in the Journal of Clinical Pharmacology found that short duration of depressive symptoms in teens can make it difficult to distinguish between actual treatment efficacy and placebo effects. This design issue may lead to unnecessary long-term drug therapy for some children, as those who recover quickly from depr...
A study published in PLoS Medicine found a possible association between the use of selective serotonin reuptake inhibitors (SSRIs) and severe violence in a small number of individuals. The authors analyzed data from various sources, including prescription-event monitoring studies and legal cases, to examine this potential link.
Researchers compared two commonly used antidepressants, nortriptyline and sertraline, to determine their effectiveness in treating postpartum depression. The study found that both drugs were effective in reducing depressive symptoms, with no significant differences in response rates or side effects.
A recent study by Carnegie Mellon and Ohio State researchers found that antidepressants are not causally linked to an increased risk of suicidality among most teens. The study suggests that only adolescents with major depressive disorder who take a specific class of antidepressants, SSRIs, may be at higher risk.
Severely depressed children and adolescents are 1.5 times more likely to attempt or complete suicide if treated with antidepressants compared to those not treated. In contrast, antidepressant use is not associated with increased risk of suicide attempts or deaths in adults.
A study suggests that ketamine, a general anesthetic agent, can rapidly alleviate depression symptoms within two hours. The effects of ketamine last for up to one week, making it a potential game-changer in treating depression with rapid onset and sustained response.
A preliminary study found that a single intravenous dose of ketamine provided symptom relief in treatment-resistant depression patients within two hours. The results suggest a new class of faster- and -longer-acting medications could be developed, pointing to potential breakthroughs in treating depression.
A large-scale study found that adding a broad-spectrum psychotropic agent, Risperidone, to standard antidepressant therapy can effectively treat resistant major depressive disorder. Patients who were less severely ill only needed a brief period of Risperidone treatment to experience lasting benefits.
A placebo study found that brain activity during a 'placebo lead-in' phase prior to antidepressant treatment can predict clinical outcomes. The study, published in the American Journal of Psychiatry, used EEG measurements to analyze changes in brain activity and its impact on depression scores.
A University of Georgia study found that three-quarters of people prescribed antidepressant drugs receive the medications for a reason not approved by the federal Food and Drug Administration. The researchers called for greater emphasis on evidence-based medicine to ensure greater safety in off-label prescribing.
A study found that mild sadness can provoke depressive thinking in some recovered patients, leading to a higher risk of relapse. Cognitive behavioral therapy and antidepressant medication were tested on 301 patients with major depressive disorder, showing that those who displayed greater cognitive reactivity were more likely to relapse.
A recent study by Dr. Wolfgang Paulus found no increased risk of congenital abnormalities in children born to mothers taking the antidepressant paroxetine during early pregnancy. The researchers suggest that a reliable pharmaco-vigilance system is crucial for documenting fetal outcomes, but more funding and support are needed.
A recent study at Mayo Clinic suggests a strong association between REM sleep behavior disorder (RBD) in younger patients and antidepressant use. The study found that 80% of RBD patients under 50 years old used antidepressants, compared to 15% of those over 50.
A study in PLoS Medicine found that US suicide rates fell from 12.2 to 10.4 per 100,000 between 1960 and 2002, coinciding with an increase in fluoxetine prescriptions from 1988 to 2002. The researchers suggest that fluoxetine may have saved up to 33,600 lives during this period.
A new study published in PLoS Medicine analyzes federal data on US suicide rates and sales of the antidepressant fluoxetine since its introduction in 1988. The research found that suicide rates dropped steadily over 14 years as sales of fluoxetine rose, with the strongest effect among women.
Phase 3 clinical trials demonstrate desvenlafaxine succinate's effectiveness in reducing depressive symptoms and improving quality of life for adult patients. The medication also showed promise in managing depression-related pain, highlighting its potential as a valuable treatment option.
Researchers found five predictors associated with bipolar disorder risk: people were unfriendly, co-morbid anxiety, depression diagnosis within five years, family history of bipolar disorder, and legal problems. These findings may help physicians better assess a patient's risk for bipolar disorder.
A recent study found that patients with diabetes who take an antidepressant medication after recovering from depression experience significantly lower rates of depression and better blood glucose control. The study, published in Archives of General Psychiatry, suggests that controlling depression can help manage blood sugar levels.
A study of 152 patients with diabetes found that taking sertraline significantly reduced the risk of depression recurrence. After one year, 65.8% of patients remained in remission compared to 47.9% on placebo.
A recent study found that patients with minor or subsyndromal depression are five and a half times more likely to be diagnosed with major depression within a year. These less-severe conditions often go undiagnosed and untreated, causing greater functional disability among the elderly population.
Researchers found a decreased risk of colorectal cancer for those taking high SSRI doses before diagnosis. The study's results provide interesting insights but highlight the need for further investigation and trial data.
The BRITE-MD trial aims to determine the accuracy of technology in predicting patient response to antidepressants, which could lead to faster recovery times. Preliminary analysis suggests high accuracy rates, but the study is currently recruiting participants.
A four-phase study on treatments for depression found that one-third of patients achieved full remission after initial treatment, while nearly 50% became symptom-free after one or two treatments. The study suggests that augmenting a first antidepressant with a second may be effective for some patients.
The STAR*D study found that switching to a new medication and augmenting the initial SSRI were effective treatment options for depression. The study showed that all three medications switched to, despite having different mechanisms of action, appeared useful options for treating depression following failure on the first SSRI.
Researchers found a significant association between genetic variation and treatment outcome for antidepressant medication. Patients with the AA gene type were 16-18% more likely to benefit from citalopram, suggesting a key role of the serotonin 2A receptor in mechanism of action.
A long-term controlled trial found that continuing antidepressants for two years can reduce the chance of another depressive episode by 60 percent. Interpersonal psychotherapy was not effective in preventing new episodes of depression in this age group.
A clinical trial tested maintenance therapy to prevent depression recurrence in patients 70 years and older. The study found that long-term antidepressant medication and psychotherapy were effective, but specific types of psychotherapy may be needed for this population.
A Harvard Medical School study found that faxing alerts to physicians about patient non-adherence to antidepressants did not increase medication adherence rates. The study, which assessed over 13,000 patients starting treatment with antidepressants, suggests that other complementary interventions are needed to improve compliance.
A two-year study found that faxes from physicians to patients with antidepressants did not increase adherence rates. The proportion of nonadherent patients remained relatively constant at about 75 percent despite the intervention.
A meta-analysis of 24 clinical trials involving over 4,500 pediatric patients found a higher risk of suicidal ideation and behavior when taking antidepressants. The FDA has required warnings and close monitoring for children taking these medications.
A study found that heart patients taking antidepressants have a 55% higher risk of dying, even after controlling for age and other factors. The researchers suggest that non-pharmocological approaches like exercise may help reduce this risk.
A mouse model of depression reveals a persistent molecular scar left by chronic stress in the brain's hippocampus. Antidepressants temporarily restore gene expression but fail to remove silencer molecules, highlighting the need for new treatments.
Researchers discovered that mice without brain-derived neurotrophic factor (BDNF) exhibit increased BDNF and gene expression in response to social defeat, leading to improved social behavior. Antidepressants reverse this effect, suggesting a potential treatment for mood disorders.
Studies show that deleting a specific gene called BDNF improves behavior in stressed mice, while also providing insight into the underlying molecular events involved. The researchers' findings have implications for understanding human ailments like social phobia and post-traumatic stress disorder.
A study by UCSD/Boston University found a small but significant increased chance of delivering an infant with severe respiratory failure (PPHN) if pregnant women take SSRIs like Prozac, Paxil, or Zoloft in the second half of pregnancy. The risk is relatively low, affecting about 6-12 mothers per thousand.
A study of 120 babies found that antidepressant use during pregnancy was associated with a 30% risk of neonatal abstinence syndrome. Infants exposed to SSRIs exhibited common symptoms such as tremor, gastrointestinal problems, and sleep disturbances.
A recent study found that discontinuing antidepressant medication during pregnancy can lead to a higher risk of depression relapse compared to continuing treatment. The study, which enrolled 201 pregnant women, suggests that women taking antidepressants who anticipate pregnancy should discuss the risks and benefits with their doctors.